Bristol-Myers Squibb Co (BMY) was Reiterated by UBS to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 80 from a previous price target of $73 . UBS advised their investors in a research report released on Apr 29, 2016.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.65. The company had revenue of $4391.00 million for the quarter, compared to analysts expectations of $4268.65 million. The company’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 EPS.
Bristol-Myers Squibb Co closed down -0.63 points or -0.89% at $70.23 with 75,72,214 shares getting traded on Wednesday. Post opening the session at $70.86, the shares hit an intraday low of $68.615 and an intraday high of $71 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 6, 2016, Lamberto Andreotti (director) sold 23,200 shares at $66.09 per share price. According to the SEC, on Mar 10, 2016, Lewis B Campbell (director) sold 2,500 shares at $66.00 per share price. On Mar 7, 2016, Joseph C Caldarella (SVP & Controller) sold 12,962 shares at $64.64 per share price, according to the Form-4 filing with the securities and exchange commission.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.